References

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

10.1016/j.cell.2021.09.020 · 2021 · External reference

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update

10.1200/jco.21.01440 · 2021 · External reference

Society for immunotherapy of cancer clinical practice guideline on immune checkpoint inhibitor-related adverse events

10.1136/jitc-2021-002435 · 2021 · External reference

Management of toxicities from immunotherapy: eSMO clinical practice guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2022.10.001 · 2022 · External reference

Immune-related adverse events in various organs caused by immune checkpoint inhibitors

10.1016/j.alit.2022.01.001 · 2022 · External reference

Immune-related adverse events of immune checkpoint inhibitors: a review

10.3389/fimmu.2023.1167975 · 2023 · External reference

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy

10.1080/25785826.2021.1976942 · 2022 · External reference

Predictive biomarkers for checkpoint inhibitor immune-related adverse events

10.3390/cancers15051629 · 2023 · External reference

Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities

10.3389/fimmu.2022.991433 · 2023 · External reference

Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review

10.1097/rhu.0000000000001777 · 2022 · External reference

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition

10.1136/jitc-2021-004008 · 2022 · External reference

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy

10.1136/jitc-2021-003625 · 2022 · External reference

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy

10.1136/jitc-2023-007236 · 2023 · External reference

Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors: a real-world study

10.3389/fimmu.2021.756872 · 2021 · External reference

Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota

10.1073/pnas.2200348119 · 2022 · External reference

Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis

10.1126/scitranslmed.abq4006 · 2023 · External reference

Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

10.1093/jjco/hyad184 · 2024 · External reference

Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events

10.1038/s41598-020-79397-6 · 2021 · External reference

Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer

10.1111/1759-7714.14063 · 2021 · External reference

Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors

10.1186/s12865-024-00599-y · 2024 · External reference

Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: a retrospective multidisciplinary study

10.1002/cam4.6724 · 2023 · External reference

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors

10.1038/s41598-021-88307-3 · 2021 · External reference

Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment

10.1186/s12885-025-15460-7 · 2025 · External reference

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity

10.1002/ehf2.14340 · 2023 · External reference

Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' Efficacy: a systematic review and meta-analysis of randomized studies

10.1016/j.esmoop.2023.100787 · 2023 · External reference

Interferon-gamma-producing CD8 + tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis

10.1053/j.gastro.2021.06.025 · 2021 · External reference

Immune checkpoint inhibitor-associated colitis: from mechanism to management

10.3389/fimmu.2021.800879 · 2021 · External reference

Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events

10.1136/jitc-2024-009742 · 2024 · External reference

Gastrointestinal and hepatobiliary immune-related adverse events: a histopathologic review

10.1097/pap.0000000000000346 · 2022 · External reference

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline

10.1530/eje-22-0689 · 2022 · External reference

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus

10.3389/fendo.2023.1213225 · 2023 · External reference

2022 ESC guidelines on cardio-oncology developed in collaboration with the EHA, ESTRO and IC-OS

10.1093/eurheartj/ehac244 · 2022 · External reference

A case study of myopericarditis due to immune checkpoint inhibitor therapy: proposed surveillance and management

10.1097/jxx.0000000000000860 · 2023 · External reference

Immune checkpoint blockade and skin toxicity pathogenesis

10.1016/j.jid.2021.06.040 · 2022 · External reference

Management and outcomes of hematological immune-related adverse events: systematic review and meta-analysis

10.1097/cji.0000000000000390 · 2022 · External reference

Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: a single-center observational study

10.1016/j.apjon.2022.100076 · 2022 · External reference

Home-based management of patients with cancer experiencing treatment-induced toxicities with a nurse-led telephone triage: the NTT study

10.1200/op.21.00192 · 2022 · External reference

Evaluation of a multidisciplinary immunotherapy toxicity monitoring program for patients receiving ipilimumab for metastatic melanoma

10.1200/op.20.00845 · 2021 · External reference

Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial

10.1001/jamanetworkopen.2022.4427 · 2022 · External reference

The feasibility, acceptability, and effectiveness of electronic patient-reported outcome symptom monitoring for immune checkpoint inhibitor toxicities: a systematic review

10.1200/cci.22.00185 · 2023 · External reference

Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors

10.1007/s00520-023-07934-w · 2023 · External reference

Co-design of an electronic patient-reported outcome symptom monitoring system for immunotherapy toxicities

10.1007/s00520-024-09034-9 · 2024 · External reference

Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial

10.1001/jama.2022.9265 · 2022 · External reference

Remote system for daily symptom monitoring during systemic anticancer treatment: patient acceptance, usability, and compliance

10.1097/ncc.0000000000000999 · 2022 · External reference

Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer

10.1038/s41598-026-42768-6 · 2026 · External reference